Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions,
and New Drug Applications – Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and
Keryx
Alternate Title:
bc-Analysts-Corner
Authors:
PR Newswire
Source:
PR Newswire US. 10/18/2013.
Document Type:
Article
Geographic Terms:
United States of America
Abstract:
NEW YORK, October 18, 2013 /PRNewswire/ — [ABSTRACT FROM PUBLISHER]
Accession Number:
201310180800PR.NEWS.USPR.enUK201310187894
Database:
Regional Business News
Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and
New Drug Applications – Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and
Keryx
This content may contain URLs/links that would redirect you to a non-EBSCO site. EBSCO does not
endorse the accuracy or accessibility of these sites, nor of the content therein.
?
Full Text
Listen
NEW YORK, October 18, 2013 /PRNewswire/ -Today, Analysts’ Corner announced new research reports highlighting Johnson & Johnson (NYSE:
JNJ), AbbVie Inc. (NYSE: ABBV), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN), and
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today’s readers may access these reports free of charge
– including full price targets, industry analysis and analyst ratings – via the links below.
Johnson & Johnson Research Report
On October 15, 2013, Johnson & Johnson released its Q3 2013
results. Johnson & Johnson registered sales of $17.6 billion in Q3 2013, up 3.1% YoY. Net earnings
attributable to Johnson & Johnson were $3.0 billion in Q3 2013, up 0.5% YoY. The Company
reported diluted EPS of $1.04 in Q3 2013, down 1.0% YoY. Commenting on the results, Alex Gorsky,
Chairman and CEO of the Company, said, “Our third-quarter results reflect the solid, demonstrable
results in achieving our near-term priorities while also advancing our longer term strategic growth
drivers.” Gorsky continued, “Our key products and successful new product launches delivered strong
growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of
new drug applications, and execution of strategic collaborations. Our investments further strengthen
our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers.”
The Full Research Report on Johnson & Johnson – including full detailed breakdown, analyst ratings
and price targets – is available to download free of charge at: